Ranbaxy Woes Continue With 30-plus Product Import Alert
This article was originally published in PharmAsia News
Executive Summary
FDA will lift a portion of its import alert for generic drugs made in two of Ranbaxy's facilities to allow the company to import antiviral ganciclovir to avoid a drug shortage